文献速递血液透析通路

老年血液透析患者的血管通路选择:AVF与AVG结局比较

Vascular access for hemodialysis in the elderly.
PubMed 文献 · J Vasc Surg · 2019-01-01

基于美国肾脏数据系统2007至2011年≥75岁血液透析患者的大样本回顾性队列,比较动静脉 fistula(AVF)与动静脉 graft(AVG)的结局。AVF起始者死亡率最低,AVF的原发通畅率更高,但AVG成熟更快;无法耐受预先行手术或需紧急导管透析者,若预期寿命>4个月应转为AVF。

要点

  • 在≥75岁可耐受手术的老年患者中,预先行AVF仍是首选透析通路。
  • AVG起始者、AVF转换者、AVG转换者及持续导管患者的死亡风险均高于AVF起始者。
  • AVF原发通畅率更高,但AVG成熟更快(中位成熟时间26天 vs 46天)。

核心结论

  • 对于可耐受手术的老年患者,预先行AVF仍是最佳的血液透析通路方式。
  • 无法耐受预先行手术或需紧急导管透析且预期寿命>4个月者,应在可行时转为AVF。
  • 若预期寿命<4个月,决定持续导管透析或转为AVG时应考虑手术风险与生活质量。

研究设计与样本

  • 回顾性分析美国肾脏数据系统2007年1月至2011年12月期间所有≥75岁、置入AVF或AVG用于血液透析的患者的资料。
  • 共纳入124,421例患者,其中AVF起始19,173例(15%)、AVG起始4,480例(4%)、AVF转换29,872例(24%)、AVG转换10,712例(9%)、持续导管透析59,824例(48%)。
  • 采用χ2检验、Student t检验、Kaplan-Meier分析及多变量Cox回归分析。

主要发现

  • 与AVF起始者相比,AVG起始者(aHR 1.24;P < .001)、AVF转换者(aHR 1.36;P < .001)、AVG转换者(aHR 1.62;P < .001)及持续导管患者(aHR 2.23;P < .001)的相对死亡风险均显著更高。
  • AVF的原发通畅率(aHR 1.21;P < .001)和原发辅助通畅率(aHR 1.31;P < .001)高于AVG。
  • AVG在最初4个月内二次通畅率更高(aHR 1.12;P < .001),但超过该时间点后AVF二次通畅率更高(aHR 1.25;P < .001)。
  • AVF与AVG的成熟率分别为80%与84%(P < .001),中位成熟时间分别为46天与26天(P < .001)。

关键数值与推荐

  • AVF起始者相对死亡风险最低,持续导管透析者相对死亡风险最高(aHR 2.23;P < .001)。
  • AVF原发通畅率优于AVG(aHR 1.21;P < .001),原发辅助通畅率亦优于AVG(aHR 1.31;P < .001)。
  • AVG成熟率84%、中位成熟时间26天;AVF成熟率80%、中位成熟时间46天(P < .001)。

临床怎么用

  • 对≥75岁可耐受手术的老年终末期肾病患者,应优先规划预先行AVF。
  • 对需紧急导管透析或无法耐受预先行手术者,若预期寿命>4个月,应在可行时转为AVF。
  • 对预期寿命<4个月者,需综合手术风险与生活质量,个体化决定持续导管透析或转为AVG。

局限性

  • 本研究为回顾性队列分析,可能存在选择偏倚和未测量混杂因素。
  • 原文摘要未报告具体的混杂因素调整变量、随访时长及数据缺失情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to compare the outcomes of arteriovenous fistulas (AVFs) with arteriovenous grafts (AVGs) in a large population-based cohort of elderly patients in the United States. METHODS: A retrospective analysis was performed of all patients ≥75 years old in the prospectively maintained United States Renal Database System who had an AVF or AVG placed for hemodialysis (HD) access between January 2007 and December 2011. Outcomes were mortality, conduit patency, maturation, time to catheter-free dialysis, and infection. A χ2 test, Student t-test, Kaplan-Meier analysis, and multivariable Cox regression analysis were employed. RESULTS: Of the 124,421 patients studied, there were 19,173 (15%) AVF initiates, 4480 (4%) AVG initiates, 29,872 (24%) AVF converts, 10,712 (9%) AVG converts, and 59,824 (48%) patients who persisted on HD catheters. Compared with AVF initiates, relative mortality was significantly higher for AVG initiates (adjusted hazard ratio [aHR], 1.24; P < .001), AVF converts (aHR, 1.36; P < .001), AVG converts (aHR, 1.62; P < .001), and catheter-persistent patients (aHR, 2.23; P < .001). Primary patency (aHR, 1.21; P < .001) and primary assisted patency (aHR, 1.31; P < .001) were higher for AVF. Secondary patency was higher for AVGs within the first 4 months (aHR, 1.12; P < .001) but higher for AVFs beyond that time point (aHR, 1.25; P < .001). Maturation rate and median time to maturation were 80% vs 84% (P < .001) and 46 vs 26 days (P < .001) for AVF vs AVG. CONCLUSIONS: Pre-emptive AVF remains the best mode of HD in elderly patients who can tolerate surgery. Patients who cannot tolerate pre-emptive surgery or have to initiate HD on an urgent basis with a catheter should convert to AVF when it is feasible if life expectancy is >4 months. If life expectancy is <4 months, surgical risk and quality of life should be considered in making the decision to persistently dialyze through HD catheter or to convert to AVG.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Arhuidese IJ, Cooper MA, Rizwan M, et al. Vascular access for hemodialysis in the elderly. J Vasc Surg. 2019. PMID: 30683199. doi:10.1016/j.jvs.2018.05.219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。